Collegium Pharmaceutical (COLL) Shares are Up 24.42%

Collegium Pharmaceutical (COLL) : Traders are bullish on Collegium Pharmaceutical (COLL) as it has outperformed the S&P 500 by a wide margin of 115.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 24.21%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 24.42% in the last 1 week, and is up 114.48% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 60.8% and the 50-Day Moving Average is 66.7%.The 200 Day SMA reached 19.73%

Collegium

Collegium Pharmaceutical (NASDAQ:COLL): After opening at $17.5, the stock dipped to an intraday low of $17.23 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $20.25 and the buying power remained strong till the end. The stock closed at $19.26 for the day, a gain of 11.07% for the day session. The total traded volume was 800,107. The stocks close on the previous trading day was $19.26.

Collegium Pharmaceutical (COLL) : The highest level Collegium Pharmaceutical (COLL) is projected to reach is $32 for the short term and the lowest estimate is at $23. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $26.4 and the possibility the share price can swing is $3.44.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Companys lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.